The conformational flexibility of the carboxy terminal residues 105-114 is a key modulator of the catalytic activity and stability of macrophage migration inhibitory factor.
Macrophage migration inhibitory factor (MIF) is a multifunctional protein and a major mediator of innate immunity. Although X-ray crystallography revealed that MIF exists as a homotrimer, its oligomerization state in vivo and the factors governing its oligomerization and stability remain poorly understood. The C-terminal region of MIF is highly conserved and participates in several intramolecular interactions that suggest a role in modulating the stability and biochemical activity of MIF. To determine the importance of these interactions, point mutations (A48P, L46A), insertions (P107) at the monomer-monomer interfaces, and C-terminal deletion (Delta 110-114NSTFA and Delta 105-114NVGWNNSTFA) variants were designed and their structural properties, thermodynamic stability, oligomerization state, catalytic activity and receptor binding were characterized using a battery of biophysical methods. The C-terminal deletion mutants DeltaC5 huMIF 1-109 and DeltaC10 huMIF 1-104 were enzymatically inactive and thermodynamically less stable than wild type MIF. Analytical ultracentrifugation studies demonstrate that both C-terminal mutants sediment as trimers and exhibit similar binding to CD74 as the wild type protein. Disrupting the conformation of the C-terminal region 105-114 and increasing its conformational flexibility through the insertion of a proline residue at position 107 was sufficient to reproduce the structural, biochemical and thermodynamic properties of the deletion mutants. P107 MIF forms an enzymatically inactive trimer and exhibits reduced thermodynamic stability relative to the wild type protein. To provide a rationale for the changes induced by these mutations at the molecular level, we also performed molecular dynamics simulations on these mutants in comparison to the wild type MIF. Together, our studies demonstrate that intersubunit interactions involving the C-terminal region 105-114, including a salt-bridge interaction between Arg73 of one monomer and the carboxy terminus of a neighboring monomer, play critical roles in modulating tertiary structure stabilization, enzymatic activity, and thermodynamic stability of MIF, but not its oligomerization state and receptor binding properties. Our results suggest that targeting the C-terminal region could provide new strategies for allosteric modulation of MIF enzymatic activity and the development of novel inhibitors of MIF tautomerase activity.
El-Turk
Farah
F
Laboratory of Molecular Neurobiology and Neuroproteomics, Brain Mind Institute, Ecole Polytechnique Federale de Lausanne, CH-1015 Lausanne, Switzerland.
Cascella
Michele
M
Ouertatani-Sakouhi
Hajer
H
Narayanan
Raghavendran Lakshmi
RL
Leng
Lin
L
Bucala
Richard
R
Zweckstetter
Markus
M
Rothlisberger
Ursula
U
Lashuel
Hilal A
HA
D000595:Amino Acid Sequence; D002850:Chromatography, Gel; D002942:Circular Dichroism; D018360:Crystallography, X-Ray; D006801:Humans; D008263:Macrophage Migration-Inhibitory Factors / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D011487:Protein Conformation; D017433:Protein Structure, Secondary; D013050:Spectrometry, Fluorescence; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014461:Ultracentrifugation
D008263:Macrophage Migration-Inhibitory Factors
J Mol Biol. 1998 Jul 3;280(1):85-102
9653033
Eur J Biochem. 1999 May;261(3):753-66
10215893
Am J Pathol. 2003 Jan;162(1):47-56
12507889
Nature. 1995 Sep 7;377(6544):68-71
7659164
Nat Med. 2000 Feb;6(2):164-70
10655104
Science. 1966 Jul 1;153(3731):80-2
5938421
FEBS Lett. 1998 Jul 3;430(3):191-6
9688536
Neurosci Lett. 1996 Aug 9;213(3):193-6
8873147
J Urol. 2005 Feb;173(2):615-20
15643275
Nature. 2000 Nov 9;408(6809):211-6
11089976
Nat Struct Biol. 1996 Mar;3(3):259-66
8605628
Diabetes Care. 2000 Feb;23(2):256-8
10868843
Mol Med. 1998 Apr;4(4):217-30
9606175
Biophys J. 2000 Mar;78(3):1606-19
10692345
FEBS Lett. 1997 Sep 8;414(2):226-32
9315691
Genes Immun. 2007 Dec;8(8):646-52
17728788
Scand J Infect Dis. 2003;35(9):573-6
14620137
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
8744570
Biophys Chem. 2004 Mar 1;108(1-3):77-87
15043922
Biochemistry. 1999 Jun 1;38(22):7346-54
10353846
Microbiol Immunol. 1999;43(1):61-7
10100748
EMBO J. 1998 Jul 1;17(13):3534-41
9649424
Protein Sci. 1996 Oct;5(10):2095-103
8897610
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9354-9
12878730
Blood. 2006 Jun 15;107(12):4807-16
16484589
Int J Biochem Cell Biol. 2006 Jan;38(1):43-55
16099194
J Med Chem. 2001 Feb 15;44(4):540-7
11170644
J Infect Dis. 2003 Jun 15;187 Suppl 2:S385-90
12792855
Biochem Biophys Res Commun. 2005 Dec 16;338(2):973-80
16286092
Nature. 2005 Nov 3;438(7064):117-21
16267559
J Endocrinol. 2003 Jan;176(1):103-10
12525254
Curr Rheumatol Rep. 2007 Oct;9(5):343-4
17915086
Inflamm Allergy Drug Targets. 2007 Sep;6(3):183-90
17897055
FEBS Lett. 1997 Nov 3;417(1):85-8
9395080
Wien Med Wochenschr. 2006 Jan;156(1-2):11-8
16465610
Nature. 1993 Oct 21;365(6448):756-9
8413654
Immunity. 2007 Mar;26(3):281-5
17376392
Proc Natl Acad Sci U S A. 1966 Jul;56(1):72-7
5229858
J Exp Med. 2003 Jun 2;197(11):1467-76
12782713
Cancer Lett. 2008 Mar 18;261(2):147-57
18171602
Biochemistry. 1997 Dec 9;36(49):15356-62
9398265
Biochemistry. 1994 Nov 29;33(47):14144-55
7947826
J Biol Chem. 1998 Jun 12;273(24):14877-84
9614090
Immunology. 1996 Nov;89(3):430-5
8958058
Mol Med. 1996 Jan;2(1):143-9
8900542
Proteins. 2005 Dec 1;61(4):704-21
16231289
Int Immunopharmacol. 2005 May;5(5):849-56
15778121